US OptionsDetailed Quotes
GRTS241018P5000
- 0.00
- 0.000.00%
15min DelayClose Oct 2 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover764.67%IV-2327.18%PremiumOct 18, 2024Expiry Date4.79Intrinsic Value100Multiplier16DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9009Delta0.6963Gamma0.04Leverage Ratio-0.0015Theta-0.0007Rho-0.04Eff Leverage0.0001Vega
Gritstone Bio Stock Discussion
this stock needs a reverse split ASAP
Gritstone bio Announces Interim Phase 2 Data for Granite Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer! Well tolerated with no advers events
Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer
Gritstone bio announced encouraging interim Phase 2 data for GRANITE, its individualized neoantigen targeting immunotherapy, in frontline microsatellite stable colorectal cancer (MSS-CRC).
The study showed a 21% relative risk reduction of progression or death with GRANITE vs. control in all treated...
spike and down again, volume slowly building up
No comment yet